LifeCycle Pharma and Sciele Pharma Announce FDA Approval of LCP-FenoChol.

Announcement no. 17/2007                                                        

To OMX Nordic Exchange Copenhagen A/S        Hørsholm, Denmark, August 11 2007 



 LifeCycle Pharma and Sciele Pharma Announce FDA Approval of New Formulation of 
              Fenofibrate in 120 mg. and 40 mg. Dosage Strengths                
                                       -                                        
          Sciele Pharma Expects U.S. Market Launch by the End of 2007           

Summary: LifeCycle Pharma and Sciele Pharma announce FDA approval of fenofibrate
in 120 mg. and 40 mg. dosage strengths.  Sciele Pharma expects U.S. market      
launch by the end of 2007.                                                      

Hørsholm, Denmark and Atlanta, Georgia, August 11, 2007; LifeCycle Pharma A/S   
(OMX:LCP) and Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that LifeCycle  
Pharma has received U.S. Food and Drug Administration (FDA) approval for        
LifeCycle Pharma's novel formulation of fenofibrate in 120-milligram and        
40-milligram dosage strengths for the treatment of hyperlipidemia and           
hypertriglyceridemia. This fenofibrate utilizes LifeCycle Pharma's Meltdose     
technology which is designed to provide enhanced absorption and greater         
bioavailability.                                                                

Under the terms of the agreement with Sciele, LifeCycle Pharma has already      
received an up-front payment of $5 million, and will receive a further $4       
million milestone payment now that this fenofibrate product has received FDA    
approval.  LifeCycle Pharma will also receive milestone payments of up to $8    
million when certain sales targets are met, and tiered royalty payments on      
product sales.  The receipt of $4 million in approval milestone does not change 
LifeCycle's financial expectations for 2007.          

This fenofibrate product will have the lowest dosage strengths of fenofibrate   
available for patients and will be marketed in the United States by Sciele      
Pharma's Primary Care sales force by the end of 2007.  Sciele Pharma currently  
has approximately 450 Primary Care sales representatives.                       

“We are pleased to receive FDA approval for our first product in the United     
States,” said Dr. Flemming Ørnskov, Chief Executive Officer of LifeCycle Pharma.
“The near-term launch of this product marks a significant step forward for our  
business model.  Sciele has a proven track record in the cardiovascular market  
with its Primary Care sales force, and we are excited about our collaboration   
with them.”                                                                     

Patrick Fourteau, Chief Executive Officer of Sciele, said, “We are enthusiastic 
about introducing LifeCycle Pharma's fenofibrate in 120-milligram and           
40-milligram dosage strengths. This fenofibrate, along with our current Triglide
product line, will enable us to increase our share of the fenofibrate market by 
broadening our offerings in this fast-growing area of the cardiovascular        
market.”                                                                        

According to the American Heart Association (AHA), over 140 million American    
adults have excessive total blood cholesterol values. Fenofibrate has proven to 
be very effective at lowering triglyceride concentrations and increasing High   
Density Lipoprotein HDL (good cholesterol). In addition, it has a superior side 
effect profile compared with alternative drugs.  Sales of fenofibrate have      
increased significantly in the last few years, and in 2006, fenofibrate sales   
totaled $1.7 billion worldwide, an increase of 16% over 2005. In the US alone,  
fenofibrate sales totaled $1.3 billion in 2006 (source: IMS).                   


For further information please contact:                                         
LifeCycle Pharma A/S                                                            
Flemming Ørnskov                                                                
President and CEO                                                               
DK Tel. +45 24 20 03 68                                                         
US Tel. +1 917 288 6446                                                         

Michael Wolff Jensen                                                            
Executive Vice President and CFO                                                
Tel. +45 40 74 62 44                                                            

                                  ---oo0oo---                                   

About LifeCycle Pharma A/S:                                                     
LifeCycle Pharma, headquartered in Hørsholm, Denmark, is an emerging            
pharmaceutical company with a broad and late stage product pipeline in          
therapeutic areas of cholesterol management, hypertension, organ transplant and 
autoimmune diseases. LifeCycle Pharma's proprietary technology platform,        
MeltDose® technology, offers lower dosing, reduced side effects and improved    
safety and patient compliance, as well as reduced product development time and  
development costs. LifeCycle Pharma is listed on the OMX Nordic Exchange under  
the trading symbol (LCP). Please visit www.lcpharma.com for further information 
about LifeCycle Pharma A/S.                                                     



About Sciele Pharma, Inc. :                                                     
Sciele Pharma, Inc., headquartered in Altlanta Georgia is a pharmaceutical      
company specializing in sales, marketing and development of branded prescription
products focused on Cardiovascular/Diabetes, Women's Health and Pediatrics. The 
Company's Cardiovascular/Diabetes products treat patients with high cholesterol,
hypertension, high triglycerides, unstable angina and Type 2 diabetes; its      
Women's Health products are designed to improve the health and well-being of    
women and mothers and their babies; and its Pediatrics products treat allergies,
asthma, coughs and colds, and Attention Deficit/Hyperactivity Disorder (ADHD).  
Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs    
more than 900 people. The Company's success is based on placing the needs of    
patients first, improving health and quality of life, and implementing its      
business platform - an Entrepreneurial Spirit, Innovation, Speed of Execution,  
Simplicity, and Teamwork.  For more information, visit:  www.sciele.com.